Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions

Cytokine and Growth Factor Reviews

Volumn 25, Issue 2, 2014, Pages 147-156

  Yi, Zuoan ^a   Lin, Wai Wai ^a   Stunz, Laura L ^a   Bishop, Gail A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

B lymphocyte; Lymphocyte activation; Signal transduction; T lymphocyte; TRAF

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CD40 ANTIGEN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; VIRUS PROTEIN; CYTOKINE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TOLL LIKE RECEPTOR; TRAF3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

B CELL LYMPHOMA; B LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; CYTOLOGY; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THYMOCYTE; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; GENETICS; IMMUNOLOGY; MOUSE;

ANIMALS; B-LYMPHOCYTES; HUMANS; MICE; NF-KAPPA B; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CYTOKINE; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TNF RECEPTOR-ASSOCIATED FACTOR 3; TOLL-LIKE RECEPTORS;

EID: 84899123621     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.12.002     Document Type: Review

References (139)

1. Xu Y., Cheng G., Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996, 5:407-415.
2. Xie P., Stunz L.L., Larison K.D., Yang B., Bishop G.A. TRAF3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007, 27:253-267.
3. Gardam S., Sierro S., Basten A., Mackay F., Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008, 28:391-401.
4. Hildebrand J.M., Yi Z., Buchta C.M., Poovassery J.S., Stunz L.L., Bishop G.A. Roles of TRAF3 and TRAF5 in immune cell function. Immunol Rev 2011, 244:55-74.
5. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
6. Weih D.S., Yilmaz Z.B., Weih F. Essential role of RelB in germinal center and MZ formation and proper expression of homing chemokines. J Immunol 2001, 167:1909-1919.
7. Franzoso G., Carlson L., Poljak L., Shores E.W., Epstein S., Leonardi A., et al. Mice deficient in NF-κB/p52 present with defects in humoral responses, GC reactions, and splenic microarchitecture. J Exp Med 1998, 187:147-159.
8. Xie P., Kraus Z.J., Stunz L.L., Liu Y., Bishop G.A. TRAF3 is required for T cell-mediated immunity and TCR/CD28 signaling. J Immunol 2011, 186(1):143-155.
9. Keats J.J., Fonesca R., Chesi M., Schop R., Baker A., Chng W.-J., et al. Promiscuous mutations activate the noncanonical NF-κB pathway in MM. Cancer Cell 2007, 12:131-144.
10. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
11. Otto C., Giefing M., Massow A., Vater I., Gesk S., Schlesner M., et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012, 157:702-708.
12. Nagel I., Bug S., Tönnies H., Ammerpohl O., Richter J., Vater I., et al. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia 2009, 23:2153-2155.
13. Moore C.R., Liu Y., Shao C., Covey L.R., Morse H.C., Xie P. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia 2012, 26:1122-1127.
14. Hu H.M., O'Rourke K., Boguski M.S., Dixit V.M. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994, 269:30069-30072.
15. Cheng G., Cleary A.M., Ye Z., Hong D.I., Lederman S., Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995, 267:1494-1498.
16. Hostager B.S., Bishop G.A. Cutting edge: contrasting roles of TRAF2 and TRAF3 in CD40-mediated B lymphocyte activation. J Immunol 1999, 162:6307-6311.
17. Pullen S.S., Miller H.G., Everdeen D.S., Dang T.T.A., Crute J.J., Kehry M.R. CD40-TRAF interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998, 37:11836-11845.
18. Hostager B.S., Haxhinasto S.A., Rowland S.R., Bishop G.A. TRAF2-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003, 278:45382-45390.
19. Haxhinasto S.A., Bishop G.A. A novel interaction between PKD and TRAFs regulates BCR-CD40 synergy. J Immunol 2003, 171:4655-4662.
20. Xie P., Hostager B.S., Bishop G.A. Requirement for TRAF3 in signaling by LMP1, but not CD40, in B lymphocytes. J Exp Med 2004, 199:661-671.
21. Bishop G.A., Hostager B.S. Signaling by CD40 and its mimics in B cell activation. Immunol Res 2001, 24:97-109.
22. Graham J.P., Arcipowski K.M., Bishop G.A. Differential B lymphocyte regulation by CD40 and its viral mimic, LMP1. Immunol Rev 2010, 237:226-248.
23. Bishop G.A., Hostager B.S., Brown K.D. Mechanisms of TRAF regulation in B lymphocytes. J Leukoc Biol 2002, 72:19-23.
24. Soni V., Cahir-McFarland E., Kieff E. LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol 2007, 597:173-187.
25. Arcipowski K.M., Stunz L.L., Graham J.P., Kraus Z.J., Vanden Bush T.J., Bishop G.A. Molecular mechanisms of TRAF6 utilization by the oncogenic viral mimic of CD40, LMP1. J Biol Chem 2011, 286:9948-9955.
26. Kraus Z.J., Nakano H., Bishop G.A. TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40. Proc Natl Acad Sci USA 2009, 106:17140-17145.
27. Wu S., Xie P., Welsh K., Li C., Ni C., Zhu X., et al. LMP1 protein from EBV is a structural decoy in B lymphocytes for binding to TRAF3. J Biol Chem 2005, 280:33620-33626.
28. Ardila-Osorio H., Clausse B., Mishal Z., Wiels J., Tursz T., Busson P. Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer 1999, 81:645-649.
29. Hostager B.S., Catlett I.M., Bishop G.A. Recruitment of CD40, TRAF2 and TRAF3 to membrane microdomains during CD40 signaling. J Biol Chem 2000, 275:15392-15398.
30. Kaykas A., Worringer K., Sugden B. CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. EMBO J 2001, 20:2641-2654.
31. Brown K.D., Hostager B.S., Bishop G.A. Differential signaling and TRAF degradation by CD40 and the EBV oncoprotein LMP1. J Exp Med 2001, 193:943-954.
32. Moore C.R., Bishop G.A. Differential regulation of CD40-mediated TRAF degradation in B lymphocytes. J Immunol 2005, 175:3780-3789.
33. Ye H., Park Y.C., Kreishman M., Kieff E., Wu H. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell 1999, 4:321-330.
34. Graham J.P., Moore C.R., Bishop G.A. Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its oncogenic mimic, LMP1. J Immunol 2009, 183:2966-2973.
35. Peters A.L., Plenge R., Graham R., Altshuler D., Moser K., Gaffney P.M., et al. A novel polymorphism of the human CD40 receptor with enhanced function. Blood 2008, 112:1863-1871.
36. Peters A.L., Bishop G.A. Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling. J Immunol 2010, 185:6555-6562.
37. Khare S.D., Hsu H. The role of TALL-1 and APRIL in immune regulation. Trends Immunol 2001, 22:61-63.
38. Do R.K.G., Chen-Kiang S. Mechanisms of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002, 13:19-25.
39. Cancro M.P. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004, 202:237-249.
40. Xu L.-G., Shu H.-B. TRAF3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kB activation and IL-10 production. J Immunol 2002, 169:6883-6889.
41. Morrison M.D., Reiley W., Zhang M., Sun S.-C. An atypical TRAF binding motif of BAFFR mediates induction of the noncanonical NF-κB signaling pathway. J Biol Chem 2005, 280:10018-10024.
42. Hatzoglou A., Roussel J., Bourgeade M.F., Rogier E., Madry C., Inoue J., et al. TNF receptor family member BCMA associates with TRAF1, TRAF2, and TRAF3 and activates NF-κB, elk-1, JNK, and p38 MAPK. J Immunol 2000, 165(3):1322-1330.
43. Shu H.B., Johnson H. B cell maturation protein is a receptor for the TNF family member TALL-1. Proc Natl Acad Sci USA 2000, 97:9156-9161.
44. Xia X., Treanor J., Senaldi G., Khare S.D., Boone T., Kelley M., et al. TACI is a TRAF-interacting receptor for TALL-1, a TNF family member involved in B cell regulation. J Exp Med 2000, 192:137-143.
45. Hildebrand J.M., Luo Z., Manske M.K., Price-Troska T., Ziesmer S.C., Lin W., et al. A BAFF-R mutation associated with Non-Hodgkin's lymphoma exhibits altered TRAF association and reveals new insights into proximal BAFF-R signaling. J Exp Med 2010, 207:2569-2579.
46. Liao G., Zhang M., Harhaj E.W., Sun S.-C. Regulation of NIK by TRAF3-induced degradation. J Biol Chem 2004, 279:26243-26250.
47. Lin W.W., Hildebrand J.M., Bishop G.A. A complex relationship between TRAF3 and non-canonical NF-κB activation in B lymphocytes. Front Immunol 2013, 4. Article 477.
48. Qian Y., Qin J., Cui G., Naramura M., Snow E.C., Ware C.F., et al. Act1, a negative regulator in CD40 and BAFF-mediated B cell survival. Immunity 2004, 21:575-587.
49. Claudio E., Sonder S.U., Saret S., Carvalho G., Ramalingam T.R., Wynn T.A., et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J Immunol 2009, 182:1617-1630.
50. Qian Y., Liu C., Hartupee J., Altuntas C.Z., Gulen M.F., Jane-Wit D., et al. The adaptor Act1 is required for IL-17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8:247-256.
51. Chang S.H., Park H., Dong C. Act1 adaptor protein is an immediate and essential signaling component of IL-17R. J Biol Chem 2006, 281:35603-35607.
52. Zhu S., Pan W., Shi P., Gao H., Zhao F., Song X., et al. Modulation of EAE through TRAF3-mediated suppression of IL-17 receptor signaling. J Exp Med 2010, 207:2647-2662.
53. Hauer J., Püschner S., Ramakrishnan P., Simon U., Bongers M., Federle C., et al. TRAF3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005, 102:2874-2879.
54. Rothe M., Pan M., Henzel W.J., Ayres T.M., Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83:1243-1252.
55. Munroe M.E., Bishop G.A. Role of TRAF2 in distinct and overlapping CD40 and TNFR2/CD120b-mediated B lymphocyte activation. J Biol Chem 2004, 279:53222-53231.
56. Hostager B.S., Bishop G.A. Role of TRAF2 in the activation of IgM secretion by CD40 and CD120b. J Immunol 2002, 168:3318-3322.
57. Peng S.L. Signaling to B cells by TLRs. Curr Opin Immunol 2005, 17:230-236.
58. Fillatreau S. Novel regulatory functions for TLR-activated B cells during intracellular bacterial infection. Immunol Rev 2011, 240:52-71.
59. Green N.M., Green N.M., Marshak-Rothstein A. TLR driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011, 23:106-112.
60. Aderem A., Ulevitch R.J. TLRs in the induction of the innate immune response. Nature 2000, 406:782-787.
61. Häcker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.-C., Wang G.G., et al. Specificity in TLR signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006, 439:204-207.
62. Oganesyan G., Saha S.K., Guo B., He J.Q., Shahangian A., Zarnegar B., et al. Critical role of TRAF3 in the TLR-dependent and independent antiviral response. Nature 2006, 439:208-211.
63. Perkins D.J., Polumuri S.K., Pennini M.E., Lai W., Xie P., Vogel S.N. Reprogramming of murine macrophages through TLR2 confers viral resistance via TRAF3-mediated, enhanced interferon production. PLoS Pathog 2013, (July):e1003479.
64. Pérez de Diego R., Sancho-Shimizu V., Lorenzo L., Puel A., Plancoulaine S., Picard C., et al. Human TRAF3 adaptor molecule deficiency leads to impaired TLR3 response and susceptibility to Herpes simplex encephalitis. Immunity 2010, 33:400-411.
65. Xie P., Poovassery J.S., Stunz L.L., Smith S.M., Schultz M.L., Carlin L.E., et al. Enhanced TLR responses of TRAF3-deficient B lymphocytes. J Leukoc Biol 2011, 90:1149-1157.
66. Buchta C.M., Bishop G.A. TRAF5 negatively regulates TLR signaling in B lymphocytes. J Immunol 2014, 192:145-150.
67. Sun L., Deng L., Ea C.K., Xia Z.P., Chen Z.J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004, 14:289-301.
68. Xie J.J., Liang J.Q., Diao L.H., Altman A., Li Y. TRAF6 regulates TCR signaling via interaction with and modification of LAT adapter. J Immunol 2013, 190:4027-4036.
69. Yi Z., Stunz L.L., Bishop G.A. TRAF3 plays a key role in the development and function of iNKT cells. J Exp Med 2013, 210:1079-1086.
70. Lee P.P., Fitzpatrick D.R., Beard C., Jessup H.K., Lehar S., Makar K.W., et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 2001, 15:763-774.
71. Tanigaki K., Tsuji M., Yamamoto N., Han H., Tsukada J., Inoue H., et al. Regulation of αβ/γδ T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity 2004, 20:611-622.
72. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat Immunol 2010, 11:197-206.
73. + T cells. J Immunol 2002, 168:1723-1729.
74. Matsuoka K., Inoue N., Sato T., Okamoto S., Hisamatsu T., Kishi Y., et al. T-bet upregulation and subsequent IL-12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 2004, 53:1303-1308.
75. Matsuda J.L., George T.C., Hagman J., Gapin L. Temporal dissection of T-bet functions. J Immunol 2007, 178:3457-3465.
76. Townsend M.J., Weinmann A.S., Matsuda J.L., Salomon R., Farnham P.J., Biron C.A., et al. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 2004, 20:477-494.
77. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
78. + regulatory T cells. Nat Immunol 2003, 4:330-336.
79. + T regulatory cells. Nat Immunol 2003, 4:337-342.
80. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8:191-197.
81. + regulatory T cells induces a scurfy-like disease. J Exp Med 2007, 204:57-63.
82. + T-cell control of viral infections. Immunol Rev 2013, 255:125-148.
83. Munroe M.E. Functional roles for T cell CD40 in infection and autoimmune disese: the role of CD40 in lymphocyte homeostasis. Semin Immunol 2009, 21:283-288.
84. So T., Croft M. Regulation of the PKCθ-NF-κB axis in T lymphocytes by the TNF-R family member OX40. Front Immunol 2012, 3:133.
85. Arch R.H., Thompson C.B. 4-1BB and Ox40 are members of a TNF-R subfamily that bind TRAFs and activate NF-κB. Mol Cell Biol 1998, 18:558-565.
86. Kawamata S., Hori T., Imura A., Takaori-Kondo A., Uchimaya T. Activation of OX40 signal transduction pathways leads to TRAF2 and TRAF5-mediated NF-κB activation. J Biol Chem 1998, 273:5805-5814.
87. Takaori-Kondo A., Hori T., Fukunaga K., Morita R., Kawamata S., Uchiyama T. Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-κB activation induced by OX40 signaling. Biochem Biophys Res Commun 2000, 272:856-863.
88. Song J., Salek-Ardakani S., Rogers P.R., Cheng M., van Parijs L., Croft M. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 2004, 5:150-158.
89. Song J., So T., Croft M. Activation of NF-κB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 2008, 180:7240-7248.
90. So T., Croft M. Regulation of PI-3 K and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Front Immunol 2013, 4:139.
91. So T., Lee S.W., Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 2008, J19(3-4):253-262.
92. Lin G.H., Snell L.M., Wortzman M.E., Clouthier D.L., Watts T.H. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology. J Immunol 2013, 190:4627-4639.
93. Lee H.W., Nam K.O., Seo S.K., Kim Y.H., Kang H., Kwon B.S. 4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes. Cell Immunol 2003, 223:143-150.
94. + memory T cells in the bone marrow. Eur J Immunol 2012, 42:2861-2874.
95. Jang I.K., Lee Z.H., Kim Y.J., Kim S.H., Kwon B.S. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate NF-κB. Biochem Biophys Res Commun 1998, 242:613-620.
96. Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A., Goldstein M.D., et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998, 187:1849-1862.
97. McPherson A.J., Snell L.M., Mak T.W., Watts T.H. Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells. J Biol Chem 2012, 287:23010-23019.
98. Sabbagh L., Srokowski C.C., Pulle G., Snell L.M., Sedgmen B.J., Liu Y., et al. A critical role for TRAF1 and Bim down-regulation in CD8 memory T cell survival. Proc Natl Acad Sci USA 2006, 103:18703-18708.
99. + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002, 169:4882-4888.
100. + T cells. PLoS ONE 2013, 8:e69677.
101. Ware C.F. Targeting the LIGHT-HVEM pathway. Adv Exp Med Biol 2009, 647:146-155.
102. Marsters S.A., Ayres T.M., Skubatch M., Gray C.L., Rothe M., Ashkenazi A. HVEM, a member of the TNFR family, interacts with members of the TRAF family and activates the transcription factors NF-κB and AP-1. J Biol Chem 1997, 272:14029-14032.
103. Soroosh P., Doherty T.A., So T., Mehta A.K., Khorram N., Norris P.S., et al. HVEM (TNFRSF14) regulates the persistence of T helper memory cell populations. J Exp Med 2011, 208:797-809.
104. Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., et al. Identification of a new member of the TNF family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999, 9:215-218.
105. Kwon B., Yu K.Y., Ni J., Yu G.L., Jang I.K., Kim Y.J., et al. Identification of a novel activation-inducible protein of the TNFR superfamily and its ligand. J Biol Chem 1999, 274:6056-6061.
106. Snell L.M., McPherson A.J., Lin G.H.Y., Sakaguchi S., Pandolfi P.P., Riccardi C., et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol 2010, 185:7223-7234.
107. Kim J.I., Sonawane S.B., Lee M.K., Lee S.-H., Duff P.E., Moore D.J., et al. Blockade of GITR-GITRL interaction maintains Treg function to prolong allograft survival. Eur J Immunol 2010, 40:1369-1374.
108. Aizawa S., Nakano H., Ishida T., Horie R., Nagai M., Ito K., et al. TRAF5 and TRAF2 are involved in CD30-mediated NF-κB activation. J Biol Chem 1997, 272:2042-2045.
109. Boucher L.M., Marengere L.E., Lu Y., Thukral S., Mak T.W. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNFR superfamily. Biochem Biophys Res Commun 1997, 233:592-600.
110. + T cells. J Immunol 2005, 175:4627-4634.
111. Sun X., Yamada H., Shibata K., Muta H., Tani K., Podack E., et al. CD30L/CD30 plays a critical role in Th17 differentiation in mice. J Immunol 2010, 185:2222-2230.
112. Reynolds J.M., Dong C. TLR regulation of effector T lymphocyte function. Trends Immunol 2013, 34:511-519.
113. + T cell survival. J Immunol 2004, 172:6065-6073.
114. Reynolds J.M., Martinez G.J., Chung Y., Dong C. TLR4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci USA 2012, 109:13064-13069.
115. + T cells. Immunology 2007, 122:149-156.
116. Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34:680-692.
117. Nakhaei P., Genin P., Civas A., Hiscott J. RIG-I-like receptors: sensing and responding to RNA virus infection. Semin Immunol 2009, 21:215-222.
118. Saha S.K., Pietras E., He J.Q., Kang J.R., Liu S.-Y., Oganesyan G., et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J 2006, 25:3257-3263.
119. Nakhaei P., Mesplede T., Solis M., Sun Q., Zhao T., Yang L., et al. The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. PLoS Pathog 2009, 5(November):e1000650.
120. + T cell survival and fitness. Immunity 2012, 37:235-248.
121. de Jong S.J., Albrecht J.C., Schmidt M., Muller-Fleckenstein I., Biesinger B. Activation of noncanonical NF-κB signaling by the oncoprotein Tio. J Biol Chem 2010, 285:16495-16503.
122. Katsch K., de Jong S.J., Schmidt M., Muller-Fleckenstein I., Fleckenstein B., Albrecht J.C., et al. Species restriction of Herpesvirus saimiri and Herpesvirus ateles: human lymphocyte transformation correlates with distinct signaling properties of viral oncoproteins. Virus Res 2012, 165:179-189.
123. Albrecht J.C., Friedrich U., Kardinal C., Koehn J., Fleckenstein B., Feller S.M., et al. Herpesvirus ateles gene product Tio interacts with nonreceptor protein tyrosine kinases. J Virol 1999, 73(June (6)):4631-4639. PubMed PMID: 10233922. Pubmed Central PMCID: 112504.
124. Heinemann S., Biesinger B., Fleckenstein B., Albrecht J.C. NFκB signaling is induced by the oncoprotein Tio through direct interaction with TRAF6. J Biol Chem 2006, 281:8565-8572.
125. de Jong S.J., Albrecht J.C., Giehler F., Kieser A., Sticht H., Biesinger B. Noncanonical NF-κB activation by the oncoprotein Tio occurs through a nonconserved TRAF3-binding motif. Sci Signal 2013, 6:ra27.
126. Albrecht J.C., Muller-Fleckenstein I., Schmidt M., Fleckenstein B., Biesinger B. Tyrosine phosphorylation of the Tio oncoprotein is essential for transformation of primary human T cells. J Virol 2005, 79:10507-10513.
127. Abraham L., Fackler O.T. HIV-1 Nef: a multifaceted modulator of TCR signaling. Cell Commun Signal 2012, 10:39.
128. Mangino G., Percario Z.A., Fiorucci G., Vaccari G., Acconcia F., Chiarabelli C., et al. HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TRAF2. PLoS ONE 2011, 6:e22982.
129. Mishra R., Chhatbar C., Singh S.K. HIV-1 Tat C-mediated regulation of TRAF3 by microRNA 32 in human microglia. J Neuroinflamm 2012, 9:131.
130. Aya K., Alhawagri M., Hagen-Stapleton A., Kitaura H., Kanagawa O., Novack D.V. NIK controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005, 115:1848-1854.
131. Jin W., Zhou X.F., Yu J., Cheng X., Sun S.C. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 2009, 113:6603-6610.
132. Hofmann J., Mair F., Greter M., Schmidt-supprian M., Becher B. NIK signaling in DC but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J Exp Med 2011, 208:1917-1929.
133. Boehm T., Scheu S., Pfeffer K., Bleul C.C. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTβR. J Exp Med 2003, 198:757-769.
134. Zhu M., Chin R.K., Christiansen P.A., Lo J.C., Liu X., Ware C., et al. NF-κB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest 2006, 116:2964-2971.
135. Elewaut D., Shaikh R.B., Hammond K.J., De Winter H., Leishman A.J., Sidobre S., et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of Vα 14i NKT cells. J Exp Med 2003, 197:1623-1633.
136. Sivakumar V., Hammond K.J., Howells N., Pfeffer K., Weih F. Differential requirement for Rel/NF-κB family members in NKT cell development. J Exp Med 2003, 197:1613-1621.
137. + regulatory T cells in mice. PLoS ONE 2013, 8:e76216.
138. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.-H., Keats J.J., Wang H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat Immunol 2008, 9:1364-1370.
139. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008, 9:1371-1378.